Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 13/20 | 0.34 |
| ▸ | FEN1 | P39748 | 12/20 | 0.34 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.33 |
| ▸ | WEE1 | P30291 | 3/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | GCKR | Q14397 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5511797 | 0.85 | MAPK14 (0.34) | — | |
| SCHEMBL12768203 | 0.83 | TSHR (0.38) | — | |
| SCHEMBL14522043 | 0.81 | F10 (0.33) | ROCK2 | |
| SCHEMBL12768201 | 0.80 | ALDH1A1 (0.32) | — | |
| SCHEMBL5509910 | 0.79 | MAPT (0.36) | — | |
| SCHEMBL14522065 | 0.78 | MAP2K2 (0.33) | ROCK2 | |
| SCHEMBL5512110 | 0.77 | GRM2 (0.39) | — | |
| SCHEMBL27756478 | 0.76 | — | — | |
| SCHEMBL14522064 | 0.76 | AR (0.36) | — | |
| SCHEMBL5999601 | 0.75 | HPGD (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812429-A2 | SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES | Portola Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7205296-B2 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205296-B2 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205296-B2 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2006039212-A2 | SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060069093-A1 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069093-A1 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | TBXAS1, TBXA2R, SERPINC1 | ALOX5AP 715/4885FEN1 1527/4885TNIK 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.